

Status: Currently Official on 14-Feb-2025
 Official Date: Official as of 01-Dec-2020
 Document Type: USP Monographs
 DocId: GUID-91955AFC-D8B8-4C7E-9BCA-9480216CB237_2_en-US
 DOI: https://doi.org/10.31003/USPNF_M25150_02_01
 DOI Ref: nb55p

© 2025 USPC
 Do not distribute

Dicyclomine Hydrochloride Oral Solution

DEFINITION

Dicyclomine Hydrochloride Oral Solution contains NLT 95.0% and NMT 105.0% of the labeled amount of dicyclomine hydrochloride ($C_{19}H_{35}NO_2 \cdot HCl$).

IDENTIFICATION

• A.

Sample: Transfer a portion of Oral Solution, equivalent to 100 mg of dicyclomine hydrochloride, to a separator containing 10 mL of [water](#) and 1 mL of [hydrochloric acid](#). Extract with two 30-mL portions of [ether](#), and discard the ether. Extract the aqueous acid solution with two 30-mL portions of [chloroform](#), transfer the chloroform extracts to a second separator containing 20 mL of [water](#) and 1 mL of [sodium hydroxide](#) solution (1 in 10), and shake. Filter the chloroform layer through [anhydrous sodium sulfate](#) into a suitable container. Add 3 mL of a freshly prepared 1-in-20 solution of [acetyl chloride](#) in [anhydrous methanol](#), prepared by cautiously adding [acetyl chloride](#) dropwise to [anhydrous methanol](#) with stirring. Evaporate under reduced pressure at room temperature until the residue has been thoroughly dried. Use the residue so obtained to prepare a potassium bromide dispersion.

Standard: Use a similarly prepared potassium bromide dispersion of [USP Dicyclomine Hydrochloride RS](#).

Acceptance criteria: The IR absorption spectrum of the *Sample* exhibits maxima and minima at the same wavelengths as those of the *Standard*.

• B. The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

Change to read:

• PROCEDURE

Buffer: Dissolve 2.72 g of [monobasic potassium phosphate](#) in 900 mL of [water](#), adjust with 10% [sodium hydroxide](#) to a pH of 7.5 ± 0.1 , and dilute with [water](#) to 1000 mL.

Mobile phase: [Acetonitrile](#) and *Buffer* (70:30)

Diluent: [Acetonitrile](#) and *Buffer* (35:65)

Standard solution: 0.1 mg/mL of [USP Dicyclomine Hydrochloride RS](#) in *Diluent*. [NOTE—This solution is stable for ▲at least▲ (USP 1-Dec-2020) 2 days.]

Sample solution: Using a “to contain” pipet, transfer a measured volume of Oral Solution, equivalent to 10.0 mg of dicyclomine hydrochloride, to a 100-mL volumetric flask. Rinse the pipet with several small portions of *Diluent*, and add the rinsings to the volumetric flask. Dilute with *Diluent* to volume.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 215 nm

Column: 4.6-mm × 15-cm; 3.5-μm packing [L7](#)

Flow rate: ▲1▲ (USP 1-Dec-2020) mL/min

Injection volume: 50 μL

System suitability

Sample: *Standard solution*

Suitability requirements

Tailing factor: NMT 1.5

Relative standard deviation: NMT 1.5%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of dicyclomine hydrochloride ($C_{19}H_{35}NO_2 \cdot HCl$) in the portion of Oral Solution taken:

$$\text{Result} = (r_U/r_S) \times (C_S/C_U) \times 100$$

r_U = peak area of dicyclomine from the *Sample solution*

r_s = peak area of dicyclomine from the *Standard solution*

C_s = concentration of [USP Dicyclomine Hydrochloride RS](#) in the *Standard solution* (mg/mL)

C_u = nominal concentration of dicyclomine hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: 95.0%–105.0%

IMPURITIES

Add the following:

▲ • LIMIT OF DICYCLOMINE RELATED COMPOUND A

Buffer: Dissolve 2.72 g of [monobasic potassium phosphate](#) in 900 mL of [water](#), adjust with [phosphoric acid](#) to a pH of 3.5, and dilute with [water](#) to 1000 mL.

Solution A: [Acetonitrile](#) and *Buffer* (55:45)

Solution B: [Acetonitrile](#) and *Buffer* (80:20)

Mobile phase: See [Table 1](#).

Table 1

Time (min)	Solution A (%)	Solution B (%)
0	100	0
20	100	0
20.1	0	100
40	0	100
40.1	100	0
50	100	0

Diluent: [Acetonitrile](#) and [water](#) (35:65)

Standard stock solution: 0.1 mg/mL of [USP Dicyclomine Related Compound A RS](#) in *Diluent*. Sonication may be used.

Standard solution: 2.0 µg/mL of [USP Dicyclomine Related Compound A RS](#) in *Diluent* from *Standard stock solution*

Sensitivity solution: 1.0 µg/mL of [USP Dicyclomine Related Compound A RS](#) in *Diluent* from *Standard solution*

Sample solution: Nominally 1.0 mg/mL of dicyclomine hydrochloride in *Diluent* prepared as follows. Transfer a measured volume of Oral Solution, equivalent to 20 mg of dicyclomine hydrochloride, to a 20-mL volumetric flask. Rinse the pipet with several small portions of *Diluent*, and add the rinsings to the volumetric flask. Dilute with *Diluent* to volume.

Chromatographic system

(See [Chromatography \(621\)](#), [System Suitability](#).)

Mode: LC

Detector: UV 215 nm

Column: 4.6-mm × 15-cm; 3.5-µm packing [L7](#)

Flow rate: 1 mL/min

Injection volume: 100 µL

System suitability

Samples: *Standard solution* and *Sensitivity solution*

Suitability requirements

Relative standard deviation: NMT 5.0%, *Standard solution*

Signal-to-noise ratio: NLT 10, *Sensitivity solution*

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of dicyclomine related compound A in the portion of Oral Solution taken:

$$\text{Result} = (r_u/r_s) \times (C_s/C_u) \times 100$$

r_u = peak response of dicyclomine related compound A from the *Sample solution*

r_s = peak response of dicyclomine related compound A from the *Standard solution*

C_s = concentration of [USP Dicyclomine Related Compound A RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of dicyclomine hydrochloride in the *Sample solution* (mg/mL)

Acceptance criteria: NMT 0.2%▲ (USP 1-Dec-2020)

ADDITIONAL REQUIREMENTS

Change to read:

- **PACKAGING AND STORAGE:** Preserve in well-closed containers. ▲Store at controlled room temperature.▲ (USP 1-Dec-2020)

Change to read:

- **USP REFERENCE STANDARDS** (11).

[USP Dicyclomine Hydrochloride RS](#)

▲ [USP Dicyclomine Related Compound A RS](#)

[1,1'-Bi(cyclohexane)]-1-carboxylic acid.

$C_{13}H_{22}O_2$ 210.32▲ (USP 1-Dec-2020)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

Topic/Question	Contact	Expert Committee
DICYCLOMINE HYDROCHLORIDE ORAL SOLUTION	Documentary Standards Support	SM32020 Small Molecules 3

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. PF 43(6)

Current DocID: GUID-91955AFC-D8B8-4C7E-9BCA-9480216CB237_2_en-US

DOI: <https://doi.org/10.31003/USPNF.M25150.02.01>

DOI ref: [nb55p](#)